Rifaxin 550 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Ziska pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. Inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase. Broad spectrum activity against many species of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.
Dosage & Administration
- Traveler's Diarrhea: For patients ≥12 years of age: 200 mg 3 times daily for 3 days
- Hepatic Encephalopathy: For patients ≥18 years of age: 550 mg 2 times daily
- Bacterial overgrowth of irritable bowel syndrome: 400 mg 3 times daily for 10 days or 550 mg 3 times daily for 14 days. Can be taken with or without food
Interaction
In vitro study suggests Rifaxin induces CYP3A4. However, in patients with normal liver function, Rifaxin at the recommended dosing regimen is not expected to induce CYP3A4.
Contraindications
Contraindicated in patients with a hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Anaphylaxis
- Angioneurotic edema
- Exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. It is not known whether Rifaximin is excreted in human milk
Precautions & Warnings
Rifaxin is not found to be effective in patients with diarrhea complicated by fever and/or blood in the stools. Discontinue Rifaxin therapy if diarrhea symptoms worsen or persist for more than 24-48 hours and consider alternative antibiotic therapy. Consider pseudomembranous colitis diagnosis in patients with diarrhea after antibacterial administration.
Use in Special Populations
Renal Impairment: The pharmacokinetics of Rifaxin in patients with impaired renal function has not been studied. Hepatic Impairment: The systemic exposure of Rifaxin was markedly elevated in patients with hepatic impairment compared to healthy subjects.
Overdose Effects
No specific information available on the treatment of overdose with Rifaxin. In case of overdose, discontinue Rifaxin, treat symptomatically and institute supportive measures as required.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.